Cybin reports positive topline data from phase 2 study of cyb003 in major depressive disorder with 79% of patients in remission after two 12mg doses

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced positive phase 2 topline safety and efficacy data for cyb003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“mdd”). “we are delighted to share tha.
CYBN Ratings Summary
CYBN Quant Ranking